DPLM Faculty Profiles — Dr. Eberhard

David Eberhard

David A. Eberhard, MD, PhD

Associate Professor

Office: 919-966-5269

E-mail: david_eberhard@med.unc.edu

Research Interests

My work focuses on translational work in molecular pathology and genomics of solid tumors, oncology drug and companion diagnostic development, and on digital image analysis. I direct the Pre-Clinical Genomic Pathology Laboratory (https://unclineberger.org/gpath ), bringing previous industry experience in oncology drug development and central reference laboratory testing for clinical trials to the translational research and development activities at UNC. My service laboratory provides sample preparation and analysis for platforms that can be applied to routine samples from cancer patients, including next-generation sequencing and RNA expression, and pathology collaboration for team efforts in Cancer Genomics.  The work in my research laboratory addresses the genomic characterization of tumors, digital image analysis of tumor histology and integration of morphology with genomics, and understanding the relationship of molecular heterogeneity in tumor cell populations to therapeutic response and tumor recurrence after treatment, as well as their implications for tumor classification.

Selected Publications

Zhao X, Wang A, Walter V, Patel NM, Eberhard DA, Hayward MC, et al.  Combined Targeted DNA Sequencing in Non-Small Cell Lung Cancer (NSCLC) Using UNCseq and NGScopy, and RNA Sequencing Using UNCqeR for the Detection of Genetic Aberrations in NSCLC. PLoS ONE 10(6): e0129280. doi:10.1371/journal.pone.0129280, 2015.

Jeck WR, Parker J, Carson CC, Shields JM, Sambade MJ, Peters EC, Burd CE, Thomas NE, Chiang DY, Liu W, Eberhard DA, Ollila D, Grilley-Olson J, Moschos S, Hayes DN, Sharpless NE. Targeted Next Generation Sequencing Identifies Clinically Actionable Mutations in Patients with Melanoma. Pigment Cell Melanoma Res 27:653-63, 2014.

McShane LM, Cavenagh MM, Lively TG, Eberhard DA, Bigbee WL, Williams PM, Mesirov JP, Polley M-Y C, Kim KY, Tricoli JV, Taylor JMG, Simon RM, Doroshow JH, Conley BA. Criteria for Use of Omics-Based Predictors in NCI-Sponsored Clinical Trials. Nature 502(7471):317-20, 2013. PMCID: PMC4180668

Potts SJ, Huff S, Lange H, Zakhorov V, Eberhard DA, Krueger JS, Hicks DG, Young GD, Johnson T, Whitney-Miller CL. Tissue pattern recognition error rates and tumor heterogeneity in gastric cancer. Applied Immunohistochem Mol Morphol, 21:21-30, 2013.

Potts SJ, Krueger J, Landis N, Eberhard DA, Young G, Schmechel S, Lange H. Evaluating tumor heterogeneity in immunohistochemistry stained breast cancer tissue. Lab Invest 92:1342-57, 2012.

Kan Z, Stinson J, Bhatt D, Stern H, Zheng J, Moorhead M, Yue P, Peters B,    Pujara K, Carlton VEH, Yuan W, Haverty PM, Li L, Wang W, Kaminker J, Eberhard DA, Waring P, Modrusan Z, Zhang Z, Stokoe D, de Sauvage F, Faham M, Seshagiri S. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466:869-873, 2010.

Varella-Garcia M, Diebold J, Eberhard DA, Geenan K, Hirschmann A, Kockx M, Nagelmeier I, Rueschoff J, Schmitt M, Arbogast S, Cappuzzo F. EGFR flourescence in-situ hybridization assay: guidelines for application to non-small cell lung cancer. J Clin Pathol 62:970-977, 2009.

Boyd ZS, Raja R, Johnson S, Eberhard DA, Lackner MR. A Tumor Sorting Protocol That Enables Enrichment of Pancreatic Adenocarcinoma Cells and Facilitation of Genetic Analyses. J Mol Diagn 11:290-297, 2009.

Eberhard DA, Giaccone G, Johnson BE. Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer: Standardization for Use in the Clinical Setting. J Clin Oncol 26:983-994, 2008.

Peters BA, Kan Z, Sebisanovic D, Pujara K, Wang Z, Hong P, Chow B, Stinson J, Carlton VE, Pham TQ, Stern H, Waring P, Hillan KJ, Eberhard DA, de Sauvage F, Zheng J, Faham M, Seshagiri S.  Highly efficient somatic-mutation identification using Escherichia coli mismatch-repair detection. Nature Methods 4:713-715, 2007.

Herbst RS, Davies AM, Natale RB, Dang TP, Murren JR, Schiller JH, Garland LL, Miller VA, Mendelson D, Van den Abbeele AD, Melenevsky Y, de Vries DJ, Eberhard DA, Lyons B, Lutzker SG, Johnson BE. Efficacy and Safety of Single Agent Pertuzumab, a HER Dimerization Inhibitor, in Patients with Non–Small-Cell Lung Cancer. Clin Cancer Res 13:6175-6181, 2007.

Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, Hainsworth JD, Garcia AA, Pegram MD, Schilder RJ, Cohn DE, Roman L, Derynck MK, Ng K, Lyons B, Allison DE, Eberhard DA, Pham TQ, Dere R, Karlan BY. Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship with Tumor HER2 Activation Status. J  Clin Oncol 24:4324-4332, 2006.

Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Jänne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisanovic D, Seshagiri S Stinson JA, Zhang YR, Hillan KJ. Mutations in the Epidermal Growth Factor Receptor and in KRAS are predictive and prognostic indicators in non-small cell lung cancers treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23:5900-5909, 2005.

Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L, Pham T, Soriano R, Stinson J, Lin C-Y, Seshagiri S, Modrusan Z, O’Neill V, Amler LC. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 11:8686-8698, 2005.

Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND, Baumber R, Lamborn KR, Kapadia A, Malec M, Berger MS, Stokoe D. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.  J Natl Cancer Inst 97:880-887, 2005.

View complete list of published work in My Bibliography